Table 1.
Patient characteristics
| Participants n (%) N = 14 | |
|---|---|
| Median age (interquartile range) | 61.5 (54, 66) |
| Race | |
| African American | 14 (100) |
| Ethnicity | |
| Non-Hispanic | 14 (100) |
| Metastatic sites | |
| Bone | 9 (64) |
| Soft tissue | 5 (36) |
| Lung | 3 (21) |
| Adrenal | 1 (7) |
| Liver | 1 (7) |
| Brain | 0 (0) |
| ECOG | |
| 0 | 8 (57) |
| 1 | 6 (43) |
| Smoking History | |
| Active Smoker | 3 (21) |
| Former Smoker | 5 (36) |
| Never Smoker | 6 (43) |
| Endocrine Therapy | |
| Letrozole | 13 (93) |
| Fulvestrant | 1 (7) |
| Ovarian Suppression Therapy | |
| None | 11 (79) |
| Goserelin or leuprolide | 3 (21) |
| Concomitant Medications | |
| Prohibited medication | 0 (0) |
| Not recommended medication | 3 (21)a |
| CYP3A5 Phenotype | |
| Normal Metabolizer (Expressor) | 1 (7) |
| Intermediate Metabolizer (Expressor) | 6 (43) |
| Poor Metabolizer (Non-expressor) | 7 (50) |
Median and interquartile range are shown for age.
aOne participant was prescribed two medications that were not recommended (metformin continued through study; atorvastatin held D-1 through D12 after completion of PK sampling) and two participants were prescribed one medication that was not recommended (ondansetron and mirtazapine).